Shares of Catalent Inc (NYSE:CTLT) have received a consensus recommendation of “Buy” from the sixteen research firms that are covering the stock, Marketbeat.com reports. Five research analysts have rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $48.78.

A number of equities analysts have weighed in on CTLT shares. Zacks Investment Research cut Catalent from a “buy” rating to a “hold” rating in a report on Tuesday, July 3rd. ValuEngine upgraded Catalent from a “hold” rating to a “buy” rating in a report on Tuesday, June 26th. Finally, JPMorgan Chase & Co. upped their price target on Catalent from $50.00 to $55.00 and gave the stock an “overweight” rating in a report on Wednesday.

NYSE CTLT opened at $41.55 on Tuesday. The company has a market capitalization of $5.80 billion, a price-to-earnings ratio of 26.13, a P/E/G ratio of 1.90 and a beta of 1.44. Catalent has a fifty-two week low of $36.73 and a fifty-two week high of $47.87. The company has a debt-to-equity ratio of 2.44, a current ratio of 2.15 and a quick ratio of 1.78.

Catalent (NYSE:CTLT) last released its quarterly earnings results on Tuesday, August 28th. The company reported $0.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.61 by $0.06. The firm had revenue of $685.30 million during the quarter, compared to analysts’ expectations of $690.69 million. Catalent had a return on equity of 20.42% and a net margin of 3.39%. Catalent’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.65 EPS. sell-side analysts forecast that Catalent will post 1.78 earnings per share for the current fiscal year.

In other Catalent news, SVP Steven L. Fasman sold 2,252 shares of the company’s stock in a transaction that occurred on Wednesday, June 20th. The stock was sold at an average price of $41.78, for a total value of $94,088.56. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 1.70% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the business. Wells Fargo & Company MN raised its position in shares of Catalent by 59.8% during the 1st quarter. Wells Fargo & Company MN now owns 1,146,493 shares of the company’s stock valued at $47,074,000 after acquiring an additional 429,061 shares in the last quarter. Dupont Capital Management Corp acquired a new stake in shares of Catalent during the 1st quarter valued at approximately $635,000. Price Capital Management Inc. acquired a new stake in shares of Catalent during the 1st quarter valued at approximately $3,837,000. Zeke Capital Advisors LLC acquired a new stake in shares of Catalent during the 1st quarter valued at approximately $289,000. Finally, Mackay Shields LLC acquired a new stake in shares of Catalent during the 1st quarter valued at approximately $5,734,000. 98.76% of the stock is currently owned by institutional investors.

About Catalent

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.

Further Reading: Google Finance Portfolio

Analyst Recommendations for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.